Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Hair follicle mesenchyme-associated PD-L1 regulates T-cell activation induced apoptosis: a potential mechanism of immune privilege.

Wang X, Marr AK, Breitkopf T, Leung G, Hao J, Wang E, Kwong N, Akhoundsadegh N, Chen L, Mui A, Carr N, Warnock GL, Shapiro J, McElwee KJ.

J Invest Dermatol. 2014 Mar;134(3):736-745. doi: 10.1038/jid.2013.368. Epub 2013 Sep 4.

2.

Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells.

Gu YZ, Xue Q, Chen YJ, Yu GH, Qing MD, Shen Y, Wang MY, Shi Q, Zhang XG.

Hum Immunol. 2013 Mar;74(3):267-76. doi: 10.1016/j.humimm.2012.12.011. Epub 2012 Dec 20.

PMID:
23261407
3.

Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.

Li W, Wang X, Chen R, Zhu H, Chen G, Sun X.

J Surg Res. 2012 Aug;176(2):e79-87. doi: 10.1016/j.jss.2011.12.009. Epub 2011 Dec 30.

PMID:
22381170
4.

Somatostatin expression in human hair follicles and its potential role in immune privilege.

Breitkopf T, Lo BK, Leung G, Wang E, Yu M, Carr N, Zloty D, Cowan B, Shapiro J, McElwee KJ.

J Invest Dermatol. 2013 Jul;133(7):1722-30. doi: 10.1038/jid.2013.53. Epub 2013 Jan 31.

5.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L.

J Thorac Oncol. 2015 Jun;10(6):910-23. doi: 10.1097/JTO.0000000000000500.

6.

Interaction of programmed death-1 and programmed death-1 ligand-1 contributes to testicular immune privilege.

Cheng X, Dai H, Wan N, Moore Y, Vankayalapati R, Dai Z.

Transplantation. 2009 Jun 27;87(12):1778-86. doi: 10.1097/TP.0b013e3181a75633.

PMID:
19543053
7.

Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack.

Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, Takigawa M, Paus R.

J Invest Dermatol. 2008 May;128(5):1196-206. Epub 2007 Dec 27.

8.

Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.

Moravej A, Karimi MH, Geramizadeh B, Azarpira N, Zarnani AH, Yaghobi R, Khosravi M, Kalani M, Gharesi-Fard B.

Immunol Invest. 2017 Jan;46(1):80-96. doi: 10.1080/08820139.2016.1225757. Epub 2016 Oct 13.

PMID:
27736253
9.

Autocrine activation of canonical BMP signaling regulates PD-L1 and PD-L2 expression in human dendritic cells.

Martínez VG, Hidalgo L, Valencia J, Hernández-López C, Entrena A, del Amo BG, Zapata AG, Vicente A, Sacedón R, Varas A.

Eur J Immunol. 2014 Apr;44(4):1031-8. doi: 10.1002/eji.201343693. Epub 2014 Feb 16.

10.

A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.

Haile ST, Horn LA, Ostrand-Rosenberg S.

Cancer Immunol Res. 2014 Jul;2(7):610-5. doi: 10.1158/2326-6066.CIR-13-0204. Epub 2014 Apr 2.

11.

The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.

Ostrand-Rosenberg S, Horn LA, Haile ST.

J Immunol. 2014 Oct 15;193(8):3835-41. doi: 10.4049/jimmunol.1401572. Review.

12.

The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.

Zhang E, Zhang X, Liu J, Wang B, Tian Y, Kosinska AD, Ma Z, Xu Y, Dittmer U, Roggendorf M, Yang D, Lu M.

PLoS One. 2011;6(10):e26196. doi: 10.1371/journal.pone.0026196. Epub 2011 Oct 14.

13.

Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.

Pittet CL, Newcombe J, Prat A, Arbour N.

J Neuroinflammation. 2011 Nov 8;8:155. doi: 10.1186/1742-2094-8-155.

14.

Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.

Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS.

PLoS One. 2015 Apr 22;10(4):e0124059. doi: 10.1371/journal.pone.0124059. eCollection 2015.

15.

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.

Shi L, Chen S, Yang L, Li Y.

J Hematol Oncol. 2013 Sep 30;6(1):74. doi: 10.1186/1756-8722-6-74. Review.

16.

The PD-1/PD-Ls pathway and autoimmune diseases.

Dai S, Jia R, Zhang X, Fang Q, Huang L.

Cell Immunol. 2014 Jul;290(1):72-9. doi: 10.1016/j.cellimm.2014.05.006. Epub 2014 May 27. Review.

PMID:
24908630
17.

Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus.

Matsuyama-Kato A, Murata S, Isezaki M, Kano R, Takasaki S, Ichii O, Konnai S, Ohashi K.

Virol J. 2012 May 21;9:94.

18.

Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.

Balan M, Mier y Teran E, Waaga-Gasser AM, Gasser M, Choueiri TK, Freeman G, Pal S.

J Biol Chem. 2015 Mar 27;290(13):8110-20. doi: 10.1074/jbc.M114.612689. Epub 2015 Feb 2.

19.

Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1.

Lauden L, Boukouaci W, Borlado LR, López IP, Sepúlveda P, Tamouza R, Charron D, Al-Daccak R.

Circ Res. 2013 Feb 1;112(3):451-64. doi: 10.1161/CIRCRESAHA.112.276501. Epub 2012 Dec 12.

20.

PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.

Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, Blank C, Schölmerich J, Hellerbrand C.

J Hepatol. 2006 Oct;45(4):520-8. Epub 2006 Jun 16.

PMID:
16876901

Supplemental Content

Support Center